Which induction therapy regimens are used for primary therapy in patients with multiple myeloma who are not transplant candidates?

Updated: Dec 31, 2018
  • Author: Sara J Grethlein, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

One of the following six regimens may be used:

  • Bortezomib 1-1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32, followed by a 10-d rest period plus melphalan 9 mg/m2 PO plus prednisone 60 mg/m2 PO, both on days 1-4; every 6 wk for four cycles then  a maintenance phase consisting of bortezomib 1-1.3 mg/m2 on days 1, 8, 22, and 29, followed by a 13-d rest period plus  melphalan 9 mg/m2 PO plus  prednisone PO 60 mg/m2; every 5 wk for five cycles [23]

  • Melphalan 0.25 mg/kg PO plus  prednisone 2 mg/kg plus  thalidomide 200 mg PO daily (escalating to 400 mg as tolerated) on days 1-4; every 6 wk [24, 25]

  • Lenalidomide 25 mg PO on days 1-21 plus  dexamethasone 40 mg PO daily on days 1-4, 9-12, and 17-20; every 28 d [18]

  • Bortezomib 1.3 mg/m2 IV on days 1, 4, 8, and 11 every 3 wk plus  dexamethasone 20 mg on the day of and the day after bortezomib [26]

  • Twelve 6-wk cycles of chemotherapy, including melphalan 0.25 mg/kg PO plus  prednisone 2 mg/kg PO for 4 d [27]

  • Lenalidomide 10 mg PO on days 1-21 plus  melphalan 0.18 mg/kg PO on days 1-4 plus dexamethasone 40 mg PO weekly; every 28 d

Alternative treatment recommendations

One of the following may be used:

  • Pegylated liposomal doxorubicin 40 mg/mplus  vincristine 1.4 mg/m2 (maximum, 2.0 mg) as an IV infusion on day 1 plus  reduced-dose dexamethasone 40 mg PO on days 1-4 [28]

  • Vincristine 0.4 mg/day plus  doxorubicin 9 mg/m2/day by continuous infusion on days 1-4 plus  dexamethasone 40 mg/day on days 1-4, 9-12, and 17-20 (odd cycles) and 40 mg/day for 4 d on even cycles; every month [29]

  • Thalidomide may be added to standard regimens in patients with myeloma who are not transplant candidates; a meta-analysis of trials demonstrated improved survival with this approach [30]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!